AstraZeneca Plc (AZN) - Financial and Strategic SWOT Analysis Review

Date: March 22, 2016
Pages: 105
Price:
US$ 125.00
License [?]:
Publisher: GlobalData
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: AB87A1E4537EN
Leaflet:

Download PDF Leaflet

AstraZeneca Plc (AZN) - Financial and Strategic SWOT Analysis Review
AstraZeneca Plc (AZN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:
  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities – A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

AstraZeneca PLC (AstraZeneca) is a global biopharmaceutical company that carries out the design, development, production and commercialization of a wide range of primary care and specialty care medicines. The company’s product portfolio includes biologics, prescription pharmaceuticals and vaccines. It offers prescription medicines for treating cardiovascular, metabolic, respiratory, cancer, inflammation, autoimmune, infection and neuroscience diseases. AstraZeneca sells its products through wholly-owned local marketing companies as well as through distributors and local representative offices. The company markets its products principally to primary care and specialty care physicians. The company operates in Europe, the Americas, Asia, Africa and Australasia. AstraZeneca is headquartered in London, the UK.

AstraZeneca Plc Key Recent Developments

Mar 03, 2016: AstraZeneca patient assistance programs provided hundreds of millions of dollars of support in 2015 to help patients afford medicines
Feb 16, 2016: Data analysis platform driving preclinical modelling capabilities in AstraZeneca launched to wider pharmaceutical industry
Feb 08, 2016: RHINOCORT Allergy Spray Now Available Over the Counter Nationally
Feb 04, 2016: Full-Year and Q4 2015 Results
Feb 04, 2016: AstraZeneca Full-Year and Q4 2015 Results

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers. - The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company. - The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably. - Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance. - Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research. - Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company
SECTION 1 - ABOUT THE COMPANY

AstraZeneca Plc - Key Facts
AstraZeneca Plc - Key Employees
AstraZeneca Plc - Key Employee Biographies
AstraZeneca Plc - Major Products and Services
AstraZeneca Plc - Pharmaceutical Pipeline Products Data
AstraZeneca Plc, Pipeline Products by Therapy Area
AstraZeneca Plc, Pipeline Products by Development Phase
AstraZeneca Plc - History
AstraZeneca Plc - Company Statement
AstraZeneca Plc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
AstraZeneca Plc - Key Manufacturing Facilities
Joint Venture

SECTION 2 – COMPANY ANALYSIS

AstraZeneca Plc - Business Description
AstraZeneca Plc - Corporate Strategy
AstraZeneca Plc - SWOT Analysis
SWOT Analysis - Overview
AstraZeneca Plc - Strengths
Strength - Strong Presence in CVMD Market
Strength - Focused Research and Development Capabilities
Strength - Leading Position
AstraZeneca Plc - Weaknesses
Weakness - Patent Infringements and Other Disputes
Weakness - Product Discontinuations
Weakness - Product Safety Concerns
AstraZeneca Plc - Opportunities
Opportunity - Product Launches and Approvals
Opportunity - Product Pipeline
Opportunity - Orphan Drug Designation
Opportunity - Business Initiatives
AstraZeneca Plc - Threats
Threat - Competitive Pressures from Generic Manufacturers
Threat - Reliance on Third Parties
Threat - Loss of Market Exclusivity
AstraZeneca Plc - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

AstraZeneca Plc, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016
AstraZeneca Plc, Pharmaceuticals & Healthcare, Deals By Type, 2010 to YTD 2016
AstraZeneca Plc, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Mar 03, 2016: AstraZeneca patient assistance programs provided hundreds of millions of dollars of support in 2015 to help patients afford medicines
Feb 16, 2016: Data analysis platform driving preclinical modelling capabilities in AstraZeneca launched to wider pharmaceutical industry
Feb 08, 2016: RHINOCORT Allergy Spray Now Available Over the Counter Nationally
Feb 04, 2016: Full-Year and Q4 2015 Results
Feb 04, 2016: AstraZeneca Full-Year and Q4 2015 Results
Feb 04, 2016: AstraZeneca Announces Full-Year and Q4 2015 Results
Dec 16, 2015: AstraZeneca continues strategic investment in China to accelerate delivery of innovative biologics and targeted medicines
Dec 15, 2015: Controlling the ‘Social Life’ of Proteins Aims to Transform Drug Discovery
Dec 14, 2015: AZ Investment Gives Local Economy Early Christmas Present
Nov 20, 2015: AstraZeneca and Sanofi exchange over 200,000 chemical compounds

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

LIST OF TABLES

AstraZeneca Plc, Key Facts
AstraZeneca Plc, Key Employees
AstraZeneca Plc, Key Employee Biographies
AstraZeneca Plc, Major Products and Services
AstraZeneca Plc, Number of Pipeline Products by Therapy Area
AstraZeneca Plc, Number of Pipeline Products by Development Stage
AstraZeneca Plc, Pipeline Products By Therapy Area and Development Phase
AstraZeneca Plc, History
AstraZeneca Plc, Subsidiaries
AstraZeneca Plc, Key Manufacturing Facilities
AstraZeneca Plc, Joint Venture
AstraZeneca Plc, Key Competitors
AstraZeneca Plc, Ratios based on current share price
AstraZeneca Plc, Annual Ratios
AstraZeneca Plc, Interim Ratios
AstraZeneca Plc, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016
AstraZeneca Plc, Pharmaceuticals & Healthcare, Deals By Type, 2010 to YTD 2016
AstraZeneca Plc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

LIST OF FIGURES

AstraZeneca Plc, Pipeline Products by Therapy Area
AstraZeneca Plc, Pipeline Products by Development Phase
AstraZeneca Plc, Performance Chart (2011 - 2015)
AstraZeneca Plc, Ratio Charts
AstraZeneca Plc, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016
AstraZeneca Plc, Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016
Skip to top


Ask Your Question

AstraZeneca Plc (AZN) - Financial and Strategic SWOT Analysis Review
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: